Denali Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	-	-	330.53	-	-
Gross Profit	-	-	330.53	-	-
Selling, General & Admin	136.56	105.44	103.35	90.48	79.06
Research & Development	418.78	396.44	423.88	358.73	265.35
Total Operating Expenses	555.34	501.88	527.23	449.21	344.41
Operating Income	-555.34	-487.34	-196.7	-340.74	-295.75
Interest Income	42.9	64.64	51.51	14.77	4.6
Other Non-Operating Income (Expense)	-	14.54	-	-	-
Total Non-Operating Income (Expense)	42.9	79.17	51.51	14.77	4.6
Pretax Income	-512.44	-422.71	-145.19	-325.97	-291.16
Provision for Income Taxes	0.1	0.07	0.03	0.02	-0.58
Net Income	-512.54	-422.77	-145.22	-325.99	-290.58
Net Income to Common	-512.54	-422.77	-145.22	-325.99	-290.58
Shares Outstanding (Basic)	173	164	137	126	122
Shares Outstanding (Diluted)	173	164	137	126	122
Shares Change (YoY)	4.97%	19.73%	9.43%	3.30%	7.83%
EPS (Basic)	-2.97	-2.57	-1.06	-2.60	-2.39
EPS (Diluted)	-2.97	-2.57	-1.06	-2.60	-2.39
Shares Outstanding	156.18	144.22	138.39	135.97	122.28
Free Cash Flow	-422.1	-363.61	-370.93	-262.55	-219.89
Free Cash Flow Per Share	-2.44	-2.21	-2.70	-2.09	-1.81
Gross Margin	-	-	100.00%	-	-
Operating Margin	-	-	-59.51%	-	-
Profit Margin	-	-	-43.94%	-	-
FCF Margin	-	-	-112.22%	-	-
EBITDA	-544.16	-479.55	-179.97	-330.36	-287.16
EBITDA Margin	-	-	-54.45%	-	-
EBIT	-555.34	-487.34	-196.7	-340.74	-295.75
EBIT Margin	-	-	-59.51%	-	-
Effective Tax Rate	-0.02%	-0.02%	-0.02%	-0.01%	0.20%

Updated Feb 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q